10-Q: Seres Therapeutics Announces Asset Sale to Nestl Amidst Going Concern Doubts

Seres Therapeutics has agreed to sell its VOWST business to Nestl for up to $335 million plus future royalties, while also reporting a net loss of $73 million for the first half of 2024 and raising concerns about its ability to continue as a going concern.

Summary

• Seres Therapeutics has entered into an agreement to sell its VOWST business to Nestl for a total consideration of up to $335 million plus future royalties.
• The deal includes an upfront payment of $100 million, two installment payments totaling $75 million, and milestone payments of up to $160 million based on future sales.
• The company reported a net loss of $73 million for the six months ended June 30, 2024, and has an accumulated deficit of $1,051.2 million.
• Seres has identified conditions that raise substantial doubt about its ability to continue as a going concern.
• The company's cash and cash equivalents totaled $71.2 million as of June 30, 2024.
• The company expects to use the proceeds from the sale to retire its debt with Oaktree Capital Management and to support the development of SER-155 and other pipeline candidates.
• The company's restructuring plan, implemented in 2023, is expected to result in savings of approximately $75 million to $85 million in 2024.
• VOWST net sales were $14.4 million for the second quarter of 2024, with a collaboration loss of $13.3 million, resulting in a net loss of $6.6 million for Seres.
• The company is also advancing SER-155, a live biotherapeutic candidate, in a Phase 1b study, with data readout anticipated in September 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with a significant negative bias. While the asset sale provides a potential lifeline, the company's financial losses, going concern doubts, and reliance on future milestones create a high level of uncertainty and risk.

Positives

• The sale of the VOWST business to Nestl provides a significant influx of capital.
• The company is on track to achieve its cost savings targets from the 2023 restructuring plan.
• The company is continuing to advance its SER-155 program, with a data readout expected in September 2024.
• VOWST has seen broad demand across both recurrent patients and healthcare providers since its launch in June 2023.

Negatives

• The company reported a net loss of $73 million for the first half of 2024.
• There are substantial doubts about the company's ability to continue as a going concern.
• The company is obligated to use the proceeds from the sale to fully retire its senior secured debt facility with Oaktree Capital Management.
• The company's share of the VOWST net loss was $6.6 million for the second quarter of 2024.

Risks

• The completion of the asset sale to Nestl is subject to stockholder approval and other conditions, and may not be completed.
• The amount of the transaction consideration is subject to various risks and uncertainties.
• The company may not be able to realize the anticipated benefits of the transaction.
• Following the transaction, the company will be smaller and less diversified.
• The company may be unable to realize the expected benefits from its restructuring and other cost reduction efforts.
• The company may be unable to raise additional capital when needed, which could force them to delay or eliminate product development programs.
• The company relies on third parties for manufacturing, which increases the risk of insufficient quantities or unacceptable costs.
• The company depends heavily on the commercial success of VOWST, which has only recently been launched.
• The company faces substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than they do.
• The company may be unable to adequately protect its proprietary technology or obtain and maintain issued patents.
• The company's future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.

Future Outlook

The company expects to use the proceeds from the sale of the VOWST business to retire its debt and to support the development of SER-155 and other pipeline candidates. The company anticipates being able to extend its cash runway into the fourth quarter of 2025, subject to material compliance with the TSA.

Management Comments

• Management plans to provide for the Companys capital requirements through receipt of the upfront payments due upon closing of the Transaction and subsequent payments that are contingent upon compliance with the TSA, as well as other potential financing transactions, including selling shares under the Companys at the market equity offering.
• Management has concluded that substantial doubt exists about the Companys ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.

Industry Context

The announcement comes amid a challenging financial environment for many biotechnology companies, with increased scrutiny on profitability and cash runway. The sale of the VOWST business reflects a strategic shift towards focusing on core pipeline assets and reducing operational costs.

Comparison to Industry Standards

• The financial results of Seres are worse than many of its peers in the biotechnology industry, particularly those with approved products.
• The company's cash burn rate is high, and its ability to generate revenue is limited to collaboration agreements and the recent launch of VOWST.
• The company's decision to sell its VOWST business is similar to other companies that have divested assets to focus on core pipeline programs.
• The company's reliance on third-party manufacturers is common in the industry, but it also introduces risks related to supply and quality.
• The company's Phase 1b study of SER-155 is similar to other early-stage clinical trials in the microbiome therapeutics space, but the data readout in September 2024 will be critical for its future development.

Related Party Transactions

• The company has significant related party transactions with Nestl, including collaboration revenue, deferred revenue, and collaboration profit/loss sharing.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern doubts and the pending asset sale.
• Employees may experience uncertainty due to the restructuring and the sale of the VOWST business.
• Customers and patients may be affected by changes in the commercialization of VOWST.
• Suppliers and creditors may be impacted by the company's financial situation and the asset sale.

Next Steps

• The company will seek stockholder approval for the asset sale to Nestl.
• The company will continue to monitor the commercialization of VOWST until the completion of the transaction.
• The company will focus on completing the SER-155 Phase 1b study and advancing other pipeline candidates.
• The company will use the proceeds from the sale to retire its debt and fund future operations.

Key Dates

Keywords

VOWST, SER-155, microbiome therapeutics, Nestl, asset sale, going concern, clinical trials, FDA approval, restructuring, debt, Oaktree, commercialization, biotherapeutics